122 related articles for article (PubMed ID: 32791535)
21. DHEA inhibits proliferation, migration and alters mesenchymal-epithelial transition proteins through the PI3K/Akt pathway in MDA-MB-231 cells.
Colín-Val Z; López-Díazguerrero NE; López-Marure R
J Steroid Biochem Mol Biol; 2021 Apr; 208():105818. PubMed ID: 33508440
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of urinary bladder cancer cell proliferation by silibinin.
Barros TMB; Lima APB; Almeida TC; da Silva GN
Environ Mol Mutagen; 2020 Apr; 61(4):445-455. PubMed ID: 32078183
[TBL] [Abstract][Full Text] [Related]
24. Brucine Suppresses Vasculogenic Mimicry in Human Triple-Negative Breast Cancer Cell Line MDA-MB-231.
Xu MR; Wei PF; Suo MZ; Hu Y; Ding W; Su L; Zhu YD; Song WJ; Tang GH; Zhang M; Li P
Biomed Res Int; 2019; 2019():6543230. PubMed ID: 30723742
[TBL] [Abstract][Full Text] [Related]
25. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling.
Jiang K; Lu Q; Li Q; Ji Y; Chen W; Xue X
Int Immunopharmacol; 2017 Jan; 42():195-202. PubMed ID: 27930970
[TBL] [Abstract][Full Text] [Related]
26. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
Wu C; Qiu S; Liu P; Ge Y; Gao X
J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
[TBL] [Abstract][Full Text] [Related]
27. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
[TBL] [Abstract][Full Text] [Related]
28. Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway.
Momeny M; Ghasemi R; Valenti G; Miranda M; Zekri A; Zarrinrad G; Javadikooshesh S; Yaghmaie M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Tumour Biol; 2016 Mar; 37(3):3913-23. PubMed ID: 26482609
[TBL] [Abstract][Full Text] [Related]
29. KR-33028, a potent inhibitor of the Na
Amith SR; Wilkinson JM; Fliegel L
Biochem Pharmacol; 2016 Oct; 118():31-39. PubMed ID: 27521504
[TBL] [Abstract][Full Text] [Related]
30. Silibinin encapsulation in polymersome: A promising anticancer nanoparticle for inducing apoptosis and decreasing the expression level of miR-125b/miR-182 in human breast cancer cells.
Hossainzadeh S; Ranji N; Naderi Sohi A; Najafi F
J Cell Physiol; 2019 Dec; 234(12):22285-22298. PubMed ID: 31073992
[TBL] [Abstract][Full Text] [Related]
31. Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells.
Baugher PJ; Krishnamoorthy L; Price JE; Dharmawardhane SF
Breast Cancer Res; 2005; 7(6):R965-74. PubMed ID: 16280046
[TBL] [Abstract][Full Text] [Related]
32. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
[TBL] [Abstract][Full Text] [Related]
33. Hydroxytyrosol and Oleuropein Inhibit Migration and Invasion of MDA-MB-231 Triple-Negative Breast Cancer Cell via Induction of Autophagy.
Lu HY; Zhu JS; Zhang Z; Shen WJ; Jiang S; Long YF; Wu B; Ding T; Huan F; Wang SL
Anticancer Agents Med Chem; 2019; 19(16):1983-1990. PubMed ID: 31333142
[TBL] [Abstract][Full Text] [Related]
34. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC.
Kim SJ; Ju JS; Kang MH; Eun JW; Kim YH; Raninga PV; Khanna KK; Győrffy B; Pack CG; Han HD; Lee HJ; Gong G; Shin Y; Mills GB; Eyun SI; Park YY
Theranostics; 2020; 10(18):7974-7992. PubMed ID: 32724453
[TBL] [Abstract][Full Text] [Related]
35. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.
Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197
[TBL] [Abstract][Full Text] [Related]
36. Synergistic Anti-proliferative Effects of Metformin and Silibinin Combination on T47D Breast Cancer Cells via hTERT and Cyclin D1 Inhibition.
Chatran M; Pilehvar-Soltanahmadi Y; Dadashpour M; Faramarzi L; Rasouli S; Jafari-Gharabaghlou D; Asbaghi N; Zarghami N
Drug Res (Stuttg); 2018 Dec; 68(12):710-716. PubMed ID: 29920623
[TBL] [Abstract][Full Text] [Related]
37. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
[TBL] [Abstract][Full Text] [Related]
38. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
39. Enhanced intrinsic migration of aggressive breast cancer cells by inhibition of Rac1 GTPase.
Zuo Y; Shields SK; Chakraborty C
Biochem Biophys Res Commun; 2006 Dec; 351(2):361-7. PubMed ID: 17064663
[TBL] [Abstract][Full Text] [Related]
40. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
